Australian Clinical Labs Ltd
ASX:ACL

Watchlist Manager
Australian Clinical Labs Ltd Logo
Australian Clinical Labs Ltd
ASX:ACL
Watchlist
Price: 2.79 AUD -1.76% Market Closed
Market Cap: 546.3m AUD

Intrinsic Value

The intrinsic value of one ACL stock under the Base Case scenario is 5.52 AUD. Compared to the current market price of 2.79 AUD, Australian Clinical Labs Ltd is Undervalued by 49%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACL Intrinsic Value
5.52 AUD
Undervaluation 49%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Australian Clinical Labs Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about ACL?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ACL valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Australian Clinical Labs Ltd.

Explain Valuation
Compare ACL to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

A sharp drop in pandemic-related testing volumes threatens to crimp ACL’s revenue and margin growth, as the company’s COVID-19 tailwind fades faster than anticipated.

Stronger competition from large, established rivals such as Sonic Healthcare and Healius puts pressure on ACL’s pricing power, potentially undermining its market-share expansion strategy in certain regions.

Rising labor costs and ongoing staff shortages in the pathology sector could squeeze ACL’s bottom line, particularly if wage inflation outpaces the company’s ability to implement productivity improvements.

Bull Theses

ACL’s ability to deepen its footprint through strategic acquisitions, such as buying out smaller pathology firms, fosters economies of scale and enhances its bargaining power with suppliers.

Its focus on specialized testing services, including genomic and molecular diagnostics, positions ACL to capture higher-margin growth opportunities as healthcare providers increasingly pivot to advanced tests for personalized medicine.

Demographic tailwinds, notably Australia’s aging population and greater need for chronic disease monitoring, support ongoing demand for ACL’s pathology offerings and provide a resilient foundation for revenue growth.

Show More Less
How do you feel about ACL?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Australian Clinical Labs Ltd

Current Assets 120.1m
Cash & Short-Term Investments 22.1m
Receivables 72.8m
Other Current Assets 25.1m
Non-Current Assets 454.8m
Long-Term Investments 2.5m
PP&E 270.1m
Intangibles 165.2m
Other Non-Current Assets 17m
Current Liabilities 216.4m
Accounts Payable 51.6m
Other Current Liabilities 164.8m
Non-Current Liabilities 187.1m
Long-Term Debt 181.8m
Other Non-Current Liabilities 5.3m
Efficiency

Free Cash Flow Analysis
Australian Clinical Labs Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Australian Clinical Labs Ltd

Revenue
741.3m AUD
Cost of Revenue
-128.2m AUD
Gross Profit
613m AUD
Operating Expenses
-545m AUD
Operating Income
68m AUD
Other Expenses
-35.6m AUD
Net Income
32.4m AUD
Fundamental Scores

ACL Profitability Score
Profitability Due Diligence

Australian Clinical Labs Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Positive ROE
51/100
Profitability
Score

Australian Clinical Labs Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

ACL Solvency Score
Solvency Due Diligence

Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average D/E
Short-Term Solvency
Positive Net Debt
24/100
Solvency
Score

Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACL Price Targets Summary
Australian Clinical Labs Ltd

Wall Street analysts forecast ACL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACL is 3.42 AUD with a low forecast of 2.93 AUD and a high forecast of 4.04 AUD.

Lowest
Price Target
2.93 AUD
5% Upside
Average
Price Target
3.42 AUD
22% Upside
Highest
Price Target
4.04 AUD
45% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ACL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one ACL stock?

The intrinsic value of one ACL stock under the Base Case scenario is 5.52 AUD.

Is ACL stock undervalued or overvalued?

Compared to the current market price of 2.79 AUD, Australian Clinical Labs Ltd is Undervalued by 49%.

Back to Top